Research analysts at BTIG Research started coverage on shares of Matinas BioPharma (NYSEAMERICAN:MTNB) in a report released on Friday, The Fly reports. The firm set a “buy” rating on the stock.
Other research analysts have also issued reports about the stock. Roth Capital began coverage on shares of Matinas BioPharma in a research report on Monday, February 11th. They set a “buy” rating and a $4.75 price target on the stock. Zacks Investment Research raised shares of Matinas BioPharma from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Tuesday, April 16th. Finally, Maxim Group reissued a “buy” rating and set a $5.00 price target on shares of Matinas BioPharma in a research report on Thursday.
Matinas BioPharma stock opened at $0.94 on Friday. Matinas BioPharma has a 1-year low of $0.32 and a 1-year high of $1.50.
A number of hedge funds have recently made changes to their positions in the business. Vivo Capital LLC bought a new stake in Matinas BioPharma in the first quarter worth about $7,432,000. Broadfin Capital LLC purchased a new position in shares of Matinas BioPharma in the first quarter worth about $2,973,000. IFP Advisors Inc increased its stake in shares of Matinas BioPharma by 222.0% in the fourth quarter. IFP Advisors Inc now owns 1,775,000 shares of the company’s stock worth $1,083,000 after purchasing an additional 1,223,828 shares in the last quarter. Victory Capital Management Inc. purchased a new position in shares of Matinas BioPharma in the first quarter worth about $1,867,000. Finally, J. Goldman & Co LP purchased a new position in shares of Matinas BioPharma in the first quarter worth about $1,139,000.
About Matinas BioPharma
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Featured Story: Technical Analysis
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.